 finish cf journey tripl
earn rais pt
messag announc select two next-gener corrector
two distinct tripl combin trial expect initi
respect pend posit outcom tripl combin
may abl treat cystic fibrosi patient provid
detail tripl combin timelin note rais price target
breath life tripl ph trial
afternoon vertex announc advanc two next-gener corrector
two distinct combin ph trial clinic progress
hing highli expect approv tez/iva pdufa regardless
highli anticip would decid two tripl combin earli year
earlier ph data see previou note newli disclos ph data show
patient mean absolut improv
baselin week treatment tripl combin
qd mg qd respect discuss regul
final design two ph trial upon complet discuss
plan initi ph trial plu tez/iva plu tez/
once-daili regimen may see data tripl trial
late
remind deuter ivacaftor see
previou note march qd dose kalydeco ivacaftor bid dose
food regardless fat content may provid longer orphan exclus vs
kalydeco well overal patent life vs kalydeco
trial design protocol depend addit data includ ph data tripl
combin well addit toxicolog studi lastli manag said
two tripl combin plan move ph trial
mutant function mutant patient besid superior efficaci
chang highest dose compar
chang highest dose see previou note
potenti qd dose believ improv safeti profil
decis tripl combin move forward moreov lung
function data substanti better initi data tripl combin
seen back juli taken togeth opinion develop put vertex
ahead competit term timelin also efficaci remind tez/iva
pdufa date februari see catalyst tabl
today focu earn call cystic fibrosi want emphas
tripl combin see stake collabor
crispr see previou note decemb crucial ensur growth
beyond tripl see sole cystic fibrosi compani
scientif innov engin vertex exercis opt-in co-develop co-
commerci crsp beta-thalassemia sickl cell diseas
written extens crsp technolog promis hemoglobinopathi beyond
crsp collabor may also provid access gene edit technolog captur
cf patient patient howev underli caus collabor
like provid growth diseas area opinion
page analyst certif import disclosur
revenu orkambi kalydeco
total cf product revenu increas net product
revenu orkambi increas increas
orkambi revenu driven continu uptak children cf age
 increas number patient treat european countri
orkambi current reimburs net product revenu kalydeco increas
increas kalydeco revenu primarili driven
rapid uptak among peopl age older certain residu
function mutat continu growth number patient treat outsid
 kalydeco current approv reimburs
rais price target base strong perform
well posit phase data support evalu compani
tripl combin phase clinic trial increas price target reflect updat
risk-adjust revenu estim base recent collabor crispr
therapeut well increas gross margin futur year result tripl
combin made adjust model base result guidanc
manag commentari compani earn call exclud
recognit revenu franc base manag commentari
call thu lower revenu estim updat sg
 estim due opex guidanc provid compani
yet provid revenu guidanc though manag note plan
upcom tez/iva pdufa date expect februari
valuat risk
valuat price target base sum-of-the-part discount
cash flow analysi includ sale orkambi kalydeco tripl combin
risk-adjust sale appli unchang discount rate
termin growth rate plu current net cash
risk risk rate valuat includ follow slower-than-expect
uptak orkambi unit state european union less favor data
upcom clinic readout unfavor regulatori decis label expans
page analyst certif import disclosur
thousand except per-shar figur
interest incom expens net non-gaap
interest incom expens net
provis incom tax non-gaap
provis incom tax
loss attribut nci
net incom attribut non-gaap
net incom attribut
page analyst certif import disclosur
